Navigation Links
First Duplex Test for Parvovirus B19 and Hepatitis A Virus Increases Safety of Human Plasma and Plasma Products
Date:10/4/2010

PLEASANTON, Calif., Oct. 4 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the cobas® TaqScreen DPX Test for use on the cobas s 201 system is now available with the CE Mark. It is the first IVD test to offer complete coverage of all human genotypes of parvovirus B19 (B19V) and hepatitis A virus (HAV) in one assay. The test is a state-of-the-art, in-vitro nucleic acid amplification technology (NAT) test which simultaneously quantifies B19V genotypes 1, 2 and 3 DNA and detects HAV genotypes I, II and III RNA in individual samples or pooled plasma samples of human origin.

The cobas® TaqScreen DPX Test uses multi-dye, real-time polymerase chain reaction (PCR) technology which allows for the simultaneous detection and identification of individual viral targets without the use of complementary discriminatory tests. The introduction of the cobas® TaqScreen DPX Test makes the cobas s 201 system the first commercially available NAT system for screening blood and plasma for six viruses.

"Roche is committed to providing the broadest coverage and most efficient screening tests to ensure the highest safety of blood and plasma products," said Paul Brown, Ph.D., President and CEO of Roche Molecular Diagnostics. "This new test is one more step toward that goal and complements our current cobas® TaqScreen tests for the detection of HIV, HCV, HBV and WNV."

The cobas® TaqScreen DPX Test can help manage the B19V burden in plasma pools and identify HAV-contaminated units. It allows plasma manufacturers to increase processing efficiency and may reduce the number of units that are discarded. The highly precise, quantitative values obtained for B19V DNA and the test's high sensitivity for HAV RNA meet current regulatory requirements for plasma intended for further manufacture.

Human plasma is fractionated into its components, such as immunoglobulins, albumin, and clotting factors, which have many therapeutic uses. These include treatment of chronic and hereditary diseases and disorders such as hemophilia and primary immunodeficiency diseases. Plasma is also used to treat patients who have suffered severe burns or trauma, and during major surgery.

The presence of B19V DNA in plasma pools as well as plasma products has been reported to be associated with the transmission of B19V by administration of plasma products, especially coagulation factors. There have also been reports on the transmission of HAV through blood and plasma products. Both B19V and HAV are not easily inactivated by traditional methods and so detection by NAT is an important step in ensuring the safety of blood and plasma products.

About Roche Blood Screening Roche is a leader in the global NAT blood screening and plasma market, which is estimated at almost 900 million CHF. Nucleic acid-based tests enable earlier detection of active viral infections than conventional antibody or antigen assays. Roche's real-time PCR-based nucleic acid assays have been used since 1998 to screen blood and plasma products. Currently, more than 225 blood banks worldwide use Roche's automated cobas s 201 system.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are legally protected by law.

(1) Not available for sale in the USFor further information please contact: Marianne van ZeelandRoche Molecular Diagnostics Communications+1 925-549-1232 (Mobile)marianne.van_zeeland@roche.com
'/>"/>

SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. IGEN AMENDS DISTRIBUTION AGREEMENT AND ANNOUNCES FIRST SPECTRUM BUILD-OUT
2. Crescendo Biologics Announces First Triple Knockout Mouse
3. PAREXEL Announces Date of First Quarter Fiscal Year 2011 Earnings Release and Conference Call
4. Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus
5. China-Biotics Hosted its First Investor Day Event
6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
7. China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results
8. SpectraSan 24 Holds First Public Health and Safety Symposium in Ohio
9. Health Robotics Releases Results of First 20 i.v.STATIONs Return On Investment (ROI) Studies in the USA and Canada
10. Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
11. Enerkem Announces Construction Start of Worlds First Municipal Waste-to-Biofuels Facility in Edmonton, Alberta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative Radiology Solutions, ... and current participant in the Phase 1 Ventures program, is leveraging regional and ... Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying medical imaging ...
(Date:6/22/2016)... ... 22, 2016 , ... The Immigrant Journey Awards , ... to North Texas and the nation, recently held its annual luncheon program. ... civic and economic vitality of North Texas. Proceeds from the event are used ...
Breaking Biology Technology:
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):